Compare Ally Financial Inc (ALLY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Inovio Pharmaceuticals Inc — how do they compare? Ally Financial Inc trades at $43.69 (market cap $13.37B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Ally Financial Inc is far larger — about 170.2× Inovio Pharmaceuticals Inc's market cap, and Ally Financial Inc pays a 2.73% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALLY | INO | |
|---|---|---|
Market Cap | $13.37B | $78.55M |
Sector | Financials | Health |
52-Week High | $47.25 | $2.87 |
52-Week Low | $35.96 | $0.66 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.81, showing minimal daily movement. The stock exhibits a bearish technical signal with recent earnings missing estimates in Q2 2026, though revenue grew 10% year-over-year. Valuation metrics appear attractive with a P/E of 10.34 and P/B below 1. Analyst consensus remains strongly bullish with a $54.40 price target, but insider selling and mixed technical indicators suggest near-term caution.
The outlook for ALLY hinges on execution amid macroeconomic pressures. Upside potential exists from solid loan growth and digital banking strength, but risks include rising provisions, competitive pressures, and interest rate sensitivity. Earnings growth in upcoming quarters is critical for sustaining investor confidence and driving the stock toward analyst targets.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
